DNA/RNA co-testing for advanced lung cancer that has stopped responding to first treatment
Part of Cancer, Lungs & breathing clinical trials.
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic non-small cell lung cancer that cannot be removed with surgery
- Standard genetic testing found no known 'driver' mutations (like EGFR, ALK, ROS1, etc.)
- Your cancer grew or you could not tolerate your first non-targeted therapy within 6 months of starting it
- You still have a sample of your tumor tissue from before you started that first treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.